Regenicin Inc
OTC:RGIN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Regenicin Inc
Total Equity
Regenicin Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Regenicin Inc
OTC:RGIN
|
Total Equity
-$6.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-27%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Total Equity
$789.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
Total Equity
$1.6B
|
CAGR 3-Years
34%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
United Therapeutics Corp
NASDAQ:UTHR
|
Total Equity
$7.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
|
Moderna Inc
NASDAQ:MRNA
|
Total Equity
$8.7B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Regenicin Inc
Glance View
Regenicin, Inc. is a biotechnology company, which specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The company is headquartered in Little Falls, New Jersey. The company went IPO on 2008-05-12. The firm is focused on developing and commercializing a lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. The firm is focused on developing its product, TempaDerm. TempaDerm cells develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas on patients, such as ulcers. Its application are used for treatment of chronic skin wounds.
See Also
What is Regenicin Inc's Total Equity?
Total Equity
-6.2m
USD
Based on the financial report for Mar 31, 2023, Regenicin Inc's Total Equity amounts to -6.2m USD.
What is Regenicin Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-27%
Over the last year, the Total Equity growth was -18%. The average annual Total Equity growth rates for Regenicin Inc have been -15% over the past three years , -17% over the past five years , and -27% over the past ten years .
